Epidemiological situation of enterobacteriaceae resistant to cephalosporins third generation in the region of Mahdia, Tunisia (2002-2014)

##plugins.themes.academic_pro.article.sidebar##

Published Oct 24, 2018
Download
pdf
Vol. 96 No. 8 (2018): Issue Aug 2018

##plugins.themes.academic_pro.article.main##

Ali Majdoub
Anis Ben Hadj Kalifa
Imen Bannour
Yassine Meksi
Mouna Ouaz
Mohamed Kheder

Abstract

Objectives: The aim of this work was to determine the prevalence and to monitor the trends of resistance to broad-spectrum cephalosporins
among various species of enterobacteria in the region of Mahdia (Tunisia) from 2002 to 2014.
Methods: A retrospective study was carried out in the microbiology laboratory at Tahar Sfar Teaching Hospital in Mahdia. Data concerning a
thirteen-year period (2002–2014). All clinical isolates of enterobacteriaceae were identified with the API 20 E system. Antimicrobial
susceptibilities were determined by disk diffusion on Mueller Hinton agar according to CA-SFM recommendations.
Results: During the study period, 25040 non-duplicate clinical strains of enterobacteriacae were identified. 2584 (10,3%) clinical isolates showed
acquired resistance to third generation cephalosporins (3rdGC). The overall frequency of resistance increased from 8% in 2002 to 16,3% in 2014.
This increase was statistically significant. High prevalence rates of 3rdGC resistance have been observed in pediatric (25,1%), in gynecologyobstetrics
(21,9%) and medecine (17,4%). E. coli (21,6%), K. pneumoniae (28,6%) and E. cloacae (30,5%) showed high prevalence rates of
broad-spectrum cephalosporin resistance.
Conclusion: The resistance rates ERC3G in our region seems to be increasing. Implementation of infection control measures and identification
of the mechanism responsible for third generation cephalosporins resistance are necessary to limit the spreading of these resistant
enterobacteriaceae in hospitals and community settings.

Keywords:

Enterobacteriaceae; Third generation cephalosporins; Resistance; Tunisia.

##plugins.themes.academic_pro.article.details##

References

  1. Gniadkowski M. Evolution du spectre étendu des bêta-lactamases par mutation. Clin Microbiol Infect 2008;14 Suppl 1:11-32.
  2. Sturm PD, Bochum ET, van Mook-Vermulst SV, Handgraaf C, Klaassen T, Melchers WJ. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands. Microb Drug Resist 2010;16:55-60.
  3. Communiqué 2013 [en ligne]. Comité de l'antibiogramme de la société Française de Microbiologie (CA-SFM) [consulté le 01/06/2014]. Disponible à l'URL : http://sfm-microbiologie.org.
  4. Boutiba I, Ghozzi R, Ben Abdallah H, Mamlouk K, Kamoun A, Ben Redjeb S. Evolution of acquired resistance to third generation Cephalosporins in Enterobacteriaceae in a Tunisian Hospital 1993-2001. Clin Microbiol Infect 2004;10:657-78.
  5. Mkaouar D, Mahjoubi F, Mezghani S, Znazen A, Ktari S, Hammami A. Étude de la résistance des entérobactéries aux céphalosporines de troisième génération dans les hôpitaux de Sfax, Tunisie (1999-2005). Med Mal Infect 2008;38:293-8.
  6. Amazian K, Fendri C, Missoum MFK, Bouzouaia N, Rahal K, Savey A et al. Multicenter pilot survey of resistant bacteria in the Mediterranean area. Eur J Clin Microbiol Infect Dis 2006;25:340-3.
  7. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y et al. Regional variation in the prevalence of extended spectrum betalactamase producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005;52:323-9.
  8. Mathai D, Rhomberg PR, Biedenbach DJ, Jones RN. The India Antimicrobial Resistance Study Group. Evaluation of the in vitro activity of six broad Spectrum bêtalactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis 2002;44:367-77.
  9. Turner PJ. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centres: 6-year report of the MYSTIC Surveillance Study (1997-2002). Diagn Microbiol Infect Dis 2005;51:281-9.
  10. Turner PJ. Extended spectrum ï¢-lactamases. Clin infect dis 2005;41:5273-5.
  11. Mayoral G, Ferreyra M, Eden A, Gueudet P, Miquel C, Lecaillon E. Évolution de la résistance des entérobactéries aux céphalosporines de troisième génération de 2000 à 2008 au centre hospitalier de Perpignan. Pathol Biol 2010;58:7-10.
  12. Gniadkowski M. Evolution and epidemiology of Extended Spectrum bêta-lactamases and ESBL-producing microorganisms. Clin Microbiol Infect 2001;7:597-608.
  13. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F et al. Prevalence and spread of extended-spectrum β-lactamase-producing. Eur Soc Clin Microbiol Infect 2008;14 Suppl 1:144-53.
  14. Arpin C, Quentin C, Grobost F, Cambau E, Robert J. Les membres du réseau ONERBA surveillance des entérobactéries productrices de β-lactamase à spectre étendu en milieu communautaire : étude multicentrique en France en 2006 190/41 RICAI 2007, Paris.
  15. Madec JY, Lazizzera C, Châtre P, Lepage G, Martin S, Lebreton P et al. Prévalence du portage des entérobactéries BLSE chez des bovines maladies et des bovines Sains 591/76 RICAI 2007, Paris.
  16. Madec JY, Lazizzera C, Châtre P, Meunier D, Martin S, Menard MF et al. Prevalence of fecal carriage of acquired expanded-spectrum cephalosporin resistance in Enterobacteriaceae strains from cattle in France. J Clin Microbiol 2008;46:1566-7.
  17. Rosselini GM, D'Andrea MM and Mugnaioli. The Spread of CTX-M-type extended-spectrum β- lactamase. Eur Soc Clin Microbiol Infect Dis 2008;14(Suppl 1):33-41.
  18. Wang A, Yang Y, Lu Q, Wang Y, Chen Y, Deng L et al. Occurrence of qnr-positive clinical isolates in Klebsiella pneumoniae producing ESBL or AmpC-type β-lactamase from five pediatric hospitals in China. FEMS Microbiol Lett 2008;283:112-6.
  19. Cambau E, Lascols C, Sougakoff W, Bébéar C, Bonnet R, Cavallo JD et al. Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. Clin Microbiol Infect 2006;12:1013-20.
  20. Jacoby GA, Chow N, Waites KB. Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 2003;47:559-62.
  21. Wiegand I, Geiss HK, Mack D, Sturenburg E, Seifert H. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol 2007;45: 1167-74.
  22. Galas M, Decousser JW, Breton N, Godard T, Allouch PY, Pina P. Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum-beta-lactamase-producing Enterobacteriaceae in France. Antimicrob Agents Chemother 2008;52:786-9.
  23. Empel J, Baraniak A, Literacka E, Mrowka A, Fiett J, Sadowy E et al. Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 2008;52:2449-54.
  24. Zhanel GG, Decorby M, Adam H, Mulvey MR, McCracken M, Lagacé-Wiens P et al. Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010;54:4684-93.
  25. Paniagua R, Valverde A, Coque TM, Baquero F, Canton R. Assessment of prevalence and changing epidemiology of extended-spectrum beta-lactamase producing Enterobacteriaceae fecal carriers using a chromogenic medium. Diagn Microbiol Infect Dis 2010;67:376-9.
  26. Rodriguez-Villalobos H, Bogaerts P, Berhin C, Bauraing C, Deplano A et al. Trends in production of extended-spectrum beta-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals. J Antimicrob Chemother 2011;66:37-47.
  27. Bogaerts P, Rodriguez-Villalobos H, Bauraing C, Deplano A, Laurent C, Berhin C et al. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered at two Belgian hospitals. Pathol Biol 2010;58:78-83.
  28. European Antimicrobial Resistance Surveillance System annual report 2008 [http://www.rivm.nl/earss/Images/EARSS%202008_final_tcm61-65020.pdf.
  29. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC et al. Risk factors for colonization with extended spectrum β-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007;13:1144-1149.
  30. Meyer E, Serr A, Schneider C, Utzolino S, Kern WV, Scholz R et al. Should we screen patients for extended-spectrum β-lactamase producing enterobacteriaceae in intensive care units? Infect Control Hosp Epidemiol 2009;30:103-105.
  31. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non hospitalized patients. J Clin Microbiol 2004;42:1089-1094.
  32. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36.
  33. Kitchel B, Sundin DR, Patel JB. Regional dissemination of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2009;53:4511-4513.
  34. Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C et al. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis 2005;40:e84-e86.
  35. Urbánek K, KoláÅ™ M, LoveÄková Y, Strojil J, Å antavá L. Influence de l'utilisation troisième génération de la famille des céphalosporines sur l'apparition de souches Klebsiella pneumoniae BLSE. J Clin Ther Pharm 2007;32:403-8.
  36. Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J. Corrélation entre l'utilisation d'antibiotiques et de résistance dans un hôpital: observations temporaires et spécifiques à la paroi. Infection 2009;37:432-7.
  37. Blanc AC Jr, Atmar RL, Wilson, Cate TR, Stager CE, Greenberg SB. Effets de exigeant une autorisation préalable pour les antimicrobiens sélectionnés: dépenses, les susceptibilités et les résultats cliniques. Clin Infect Dis 1997;25:230-9.
  38. Haller P, Tschudin S, Dangel M. Augmentation des isolats résistants Enterobacter et corrélation avec la consommation d'antibiotiques au niveau Ward, affiche Présenté en 16. Congrès Européen de microbiologie clinique et des maladies infectieuses (ECCMID), Nice. 2006. [http://www.spitalpharmazie-basel.ch/ pdf/ ECCMID_Haller.pdf] Consulté le 12 Avril, 2015.
  39. Bosso JA, Mauldin PD, Salgado CD. The association between antibiotic use and resistance: the role of secondary antibiotics. Eur J Clin Microbiol Infect Dis 2010;29:1125-9.
  40. Meyer E, Lapatschek M, Bechtold A, Schwarzkopf G, Gastmeier P, Schwab F. Impact de la restriction de céphalosporines de troisième génération sur la charge de céphalosporine de troisième génération résistant K. pneumoniae et E. coli dans une unité de soins intensifs. Intensive Care Med 2009;35:862-70.
  41. Husickova V, Cekanova L, Chroma M, Htoutou-Sedlakova M, Hricová K, Kolar M. Transport de ESBL et AmpC positifs entérobactéries dans le tractus gastro-intestinal de sujets communautaires et les patients hospitalisés dans la République tchèque. Biomed Pap Med Fac Univ Palacky d'Olomouc Czech Répu 2012;156:348-53.
  42. Husickova V, Htoutou-Sedlakova M, Matouskova I, Chroma M, Kolar M. Analyse des entérobactéries production à large spectre bêta-lactamases dans le cadre de l'unité de soins intensifs. Ouvrez J Med Microbiol 2013;3:56-61.